Foster Victor Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 27,966 shares of the medical instruments supplier's stock, valued at approximately $6,406,000.
A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Norges Bank bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $735,523,000. T. Rowe Price Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 36.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after acquiring an additional 3,219,317 shares during the period. Kovitz Investment Group Partners LLC raised its holdings in Becton, Dickinson and Company by 392.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after acquiring an additional 2,722,829 shares during the period. First Eagle Investment Management LLC grew its position in shares of Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after purchasing an additional 1,057,879 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 15.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after purchasing an additional 810,345 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Raymond James lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $219.22.
Read Our Latest Stock Report on Becton, Dickinson and Company
Insider Activity at Becton, Dickinson and Company
In related news, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president now owns 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Byrd sold 459 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares of the company's stock, valued at $1,598,960. The trade was a 6.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,104 shares of company stock worth $399,675. Company insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Trading Down 0.7%
NYSE BDX traded down $1.14 during trading on Monday, hitting $171.07. The stock had a trading volume of 494,888 shares, compared to its average volume of 1,970,034. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market capitalization of $49.03 billion, a price-to-earnings ratio of 28.42, a P/E/G ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The stock has a 50 day simple moving average of $183.03 and a 200 day simple moving average of $212.95.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.17 earnings per share. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.43%. Becton, Dickinson and Company's payout ratio is 79.39%.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
